Nivolumab plus ipilimumab for chemotherapy-refractory metastatic castration-resistant prostate cancer: results from the randomized portion of the phase 2 CheckMate 650 trial

Journal:

Nature Communications

Published:

2026-05-08

DOI:

10.1038/s41467-026-72242-w

Affiliations:

26

Authors:

29

Go to article

Institutions	Authors	Share
Bristol-Myers Squibb, United States of America (USA)	7.000000	0.24
The University of Texas MD Anderson Cancer Center, United States of America (USA)	5.000000	0.17
Medical University of Vienna (MUW), Austria	1.000000	0.03
Hospital of the University of Montreal (CHUM), Canada	1.000000	0.03
Instituto de Investigación Hospital 12 de Octubre (i+12), Spain	1.000000	0.03
University of Tübingen (Uni Tübingen), Germany	1.000000	0.03
Nicolaus Copernicus Provincial Hospital in Koszalin, Poland	1.000000	0.03
The University of Chicago Medicine, United States of America (USA)	1.000000	0.03
IRCCS National Cancer Institute (INT) Milan, Italy	1.000000	0.03
Maria Sklodowska-Curie National Research Institute of Oncology, Poland	1.000000	0.03
Minnesota Oncology, United States of America (USA)	1.000000	0.03
TU Dresden, Germany	1.000000	0.03
Gregorio Marañon University Hospital, Spain	1.000000	0.03
Northwest Georgia Oncology Centers (NGOC), United States of America (USA)	1.000000	0.03
Odense University Hospital (OUH), Denmark	1.000000	0.03
Copenhagen University Hospital (CUH), Denmark	1.000000	0.03
Hospital Infanta Cristina, Spain	1.000000	0.03
Washington University in St. Louis (WUSTL), United States of America (USA)	1.000000	0.03
Gosford Hospital, Australia	0.500000	0.02
The University of Newcastle (UON), Australia	0.500000	0.02

Interested in Oncology and Carcinogenesis?